📰 Study Comparing News
Study Comparing News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Study Comparing. Real-time updates on events, politics, business and more.
April 22, 2024
New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse ...
April 10, 2024
The indication is for adult patients with multiple myeloma who are refractory to lenalidomide and have previously received at least 1 line of therapy.
April 6, 2024
New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse ...
February 23, 2024
CARVYKTI® is the first CAR-T therapy for patients with relapsed and refractory multiple myeloma to receive a positive CHMP opinion for second line treatment ...
February 23, 2024
23.02.2024 - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expansion of the CARVYKTI ...
June 5, 2023
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that results from the Phase 3 CARTITUDE-4 study showed CARVYKTI®...
June 5, 2023
At 16 months median follow-up, cilta-cel significantly improved progression-free survival compared to two standard of care treatment regimens1 ...
May 25, 2023
The application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, evaluating the safety and efficacy of cilta-cel in the treatment of patients with relapsed